[
    {
        "id": "article-18212_6",
        "title": "Benign Prostatic Hyperplasia -- Introduction",
        "content": "The development of\u00a0BPH is characterized by stromal and epithelial cell proliferation in the prostate transition zone, which surrounds the urethra. This leads to urethral compression and bladder outflow obstruction, which can result in clinical manifestations of LUTS, urinary retention, or infections due to incomplete bladder emptying. [5] Long-term, untreated disease can lead to the development of chronic high-pressure retention (a potentially life-threatening condition) and long-term or permanent changes to the bladder detrusor muscle.",
        "contents": "Benign Prostatic Hyperplasia -- Introduction. The development of\u00a0BPH is characterized by stromal and epithelial cell proliferation in the prostate transition zone, which surrounds the urethra. This leads to urethral compression and bladder outflow obstruction, which can result in clinical manifestations of LUTS, urinary retention, or infections due to incomplete bladder emptying. [5] Long-term, untreated disease can lead to the development of chronic high-pressure retention (a potentially life-threatening condition) and long-term or permanent changes to the bladder detrusor muscle."
    },
    {
        "id": "Pathology_Robbins_3495",
        "title": "Pathology_Robbins",
        "content": "Hydronephrosis refers to dilation of the renal pelvis and calyces, with accompanying atrophy of the parenchyma, caused by obstruction to the outflow of urine. The obstruction may be sudden or insidious, and it may occur at any level of the urinary tract, from the urethra to the renal pelvis. The most common causes are categorized as follows: Congenital, such as atresia of the urethra, valve formations in either the ureter or urethra, an aberrant renal artery compressing the ureter, renal ptosis with torsion, or kinking of the ureter Foreign bodies, such as calculi or sloughed necrotic papillae Proliferative lesions, such as benign prostatic hyperplasia, carcinoma of the prostate, bladder tumors (papilloma and carcinoma), contiguous malignant disease (retroperitoneal lymphoma, and carcinoma of the cervix or uterus) Inflammatory lesions, such as prostatitis, ureteritis, urethritis, and retroperitoneal fibrosis",
        "contents": "Pathology_Robbins. Hydronephrosis refers to dilation of the renal pelvis and calyces, with accompanying atrophy of the parenchyma, caused by obstruction to the outflow of urine. The obstruction may be sudden or insidious, and it may occur at any level of the urinary tract, from the urethra to the renal pelvis. The most common causes are categorized as follows: Congenital, such as atresia of the urethra, valve formations in either the ureter or urethra, an aberrant renal artery compressing the ureter, renal ptosis with torsion, or kinking of the ureter Foreign bodies, such as calculi or sloughed necrotic papillae Proliferative lesions, such as benign prostatic hyperplasia, carcinoma of the prostate, bladder tumors (papilloma and carcinoma), contiguous malignant disease (retroperitoneal lymphoma, and carcinoma of the cervix or uterus) Inflammatory lesions, such as prostatitis, ureteritis, urethritis, and retroperitoneal fibrosis"
    },
    {
        "id": "Pathoma_Husain_319",
        "title": "Pathoma_Husain",
        "content": "E. Sterile pyuria is the presence of pyuria (> 10 WBCs/hpf and leukocyte esterase) with a negative urine culture. 1. Suggests urethritis due to Chlamydia trachomatis or Neisseria gonorrhoeae (dominant presenting sign of urethritis is dysuria) III. PYELONEPHRITIS A. Infection of the kidney 1. Usually due to ascending infection; increased risk with vesicoureteral reflux B. Presents with fever, flank pain, WBC casts, and leukocytosis in addition to symptoms of cystitis C. Most common pathogens are 1. E coli (90%) 2. 3. IV. CHRONIC PYELONEPHRITIS A. Interstitial fibrosis and atrophy of tubules due to multiple bouts of acute pyelonephritis B. Due to vesicoureteral reflux (children) or obstruction (e.g., BPH or cervical carcinoma) C. Leads to cortical scarring with blunted calyces; scarring at upper and lower poles is characteristic of vesicoureteral reflux.",
        "contents": "Pathoma_Husain. E. Sterile pyuria is the presence of pyuria (> 10 WBCs/hpf and leukocyte esterase) with a negative urine culture. 1. Suggests urethritis due to Chlamydia trachomatis or Neisseria gonorrhoeae (dominant presenting sign of urethritis is dysuria) III. PYELONEPHRITIS A. Infection of the kidney 1. Usually due to ascending infection; increased risk with vesicoureteral reflux B. Presents with fever, flank pain, WBC casts, and leukocytosis in addition to symptoms of cystitis C. Most common pathogens are 1. E coli (90%) 2. 3. IV. CHRONIC PYELONEPHRITIS A. Interstitial fibrosis and atrophy of tubules due to multiple bouts of acute pyelonephritis B. Due to vesicoureteral reflux (children) or obstruction (e.g., BPH or cervical carcinoma) C. Leads to cortical scarring with blunted calyces; scarring at upper and lower poles is characteristic of vesicoureteral reflux."
    },
    {
        "id": "Pathoma_Husain_1",
        "title": "Pathoma_Husain",
        "content": "2. For example, cardiac myocytes undergo hypertrophy, not hyperplasia, in response to systemic hypertension (Fig. 1.1). E. Pathologic hyperplasia (e.g., endometrial hyperplasia) can progress to dysplasia and, eventually, cancer. 1. A notable exception is benign prostatic hyperplasia (BPH), which does not increase the risk for prostate cancer. III. ATROPHY A. A decrease in stress (e.g., decreased hormonal stimulation, disuse, or decreased nutrients/blood supply) leads to a decrease in organ size (atrophy). 1. Occurs via a decrease in the size and number of cells B. Decrease in cell number occurs via apoptosis. C. Decrease in cell size occurs via ubiquitin-proteosome degradation of the cytoskeleton and autophagy of cellular components. 1. In ubiquitin-proteosome degradation, intermediate filaments of the cytoskeleton are \"tagged\" with ubiquitin and destroyed by proteosomes. 2.",
        "contents": "Pathoma_Husain. 2. For example, cardiac myocytes undergo hypertrophy, not hyperplasia, in response to systemic hypertension (Fig. 1.1). E. Pathologic hyperplasia (e.g., endometrial hyperplasia) can progress to dysplasia and, eventually, cancer. 1. A notable exception is benign prostatic hyperplasia (BPH), which does not increase the risk for prostate cancer. III. ATROPHY A. A decrease in stress (e.g., decreased hormonal stimulation, disuse, or decreased nutrients/blood supply) leads to a decrease in organ size (atrophy). 1. Occurs via a decrease in the size and number of cells B. Decrease in cell number occurs via apoptosis. C. Decrease in cell size occurs via ubiquitin-proteosome degradation of the cytoskeleton and autophagy of cellular components. 1. In ubiquitin-proteosome degradation, intermediate filaments of the cytoskeleton are \"tagged\" with ubiquitin and destroyed by proteosomes. 2."
    },
    {
        "id": "article-30833_30",
        "title": "Urethral Strictures -- History and Physical",
        "content": "A key difference between benign prostatic hyperplasia and urethral stricture disease is obstructed ejaculation. [8] In addition, patients with urethral strictures do not respond to typical benign prostatic hyperplasia therapy, such as alpha-blocker medications, and the weak urinary stream is relatively constant without much variation.",
        "contents": "Urethral Strictures -- History and Physical. A key difference between benign prostatic hyperplasia and urethral stricture disease is obstructed ejaculation. [8] In addition, patients with urethral strictures do not respond to typical benign prostatic hyperplasia therapy, such as alpha-blocker medications, and the weak urinary stream is relatively constant without much variation."
    },
    {
        "id": "article-42967_6",
        "title": "Terazosin -- Administration",
        "content": "Terazosin is available in the US in oral capsule formulations as a hydrochloride salt, available in 1 mg, 2 mg, 5 mg, and 10 mg formulations. For the FDA-approved indications of hypertension and benign prostatic hyperplasia, the dosing route, frequency, and amount\u00a0are as follows: Hypertension The initial dose\u00a0is 1 mg to 10 mg orally daily, titrated upwards as needed to a maximum of 20 mg daily. Considered a second-line agent due to adverse effects, additional consideration as an agent if the patient experiences lower urinary tract symptoms associated with benign prostatic hyperplasia. [15] [16] Benign Prostatic Hyperplasia The initial dose is 1 mg to 10 mg orally at bedtime, titrated upwards as needed based upon patient response up to 20 mg daily in 1 or 2 divided doses. [17] For Non-FDA approved indications,  including medical expulsive therapy, chronic prostatitis, hyperlipidemia, urethritis, hyperhidrosis, and oligospermia:",
        "contents": "Terazosin -- Administration. Terazosin is available in the US in oral capsule formulations as a hydrochloride salt, available in 1 mg, 2 mg, 5 mg, and 10 mg formulations. For the FDA-approved indications of hypertension and benign prostatic hyperplasia, the dosing route, frequency, and amount\u00a0are as follows: Hypertension The initial dose\u00a0is 1 mg to 10 mg orally daily, titrated upwards as needed to a maximum of 20 mg daily. Considered a second-line agent due to adverse effects, additional consideration as an agent if the patient experiences lower urinary tract symptoms associated with benign prostatic hyperplasia. [15] [16] Benign Prostatic Hyperplasia The initial dose is 1 mg to 10 mg orally at bedtime, titrated upwards as needed based upon patient response up to 20 mg daily in 1 or 2 divided doses. [17] For Non-FDA approved indications,  including medical expulsive therapy, chronic prostatitis, hyperlipidemia, urethritis, hyperhidrosis, and oligospermia:"
    },
    {
        "id": "article-27473_54",
        "title": "Bladder Post Void Residual Volume -- Clinical Significance -- Obstruction",
        "content": "One researcher found that 9.5% of admitted patients to a geriatric unit with acute kidney injury had a pre-existing renal disease caused by obstructive uropathy. [41] Bladder outlet obstruction, namely benign prostatic hyperplasia, leads to profound changes and permanent damage to bladder structure and function, which may be irreversible. [42]",
        "contents": "Bladder Post Void Residual Volume -- Clinical Significance -- Obstruction. One researcher found that 9.5% of admitted patients to a geriatric unit with acute kidney injury had a pre-existing renal disease caused by obstructive uropathy. [41] Bladder outlet obstruction, namely benign prostatic hyperplasia, leads to profound changes and permanent damage to bladder structure and function, which may be irreversible. [42]"
    },
    {
        "id": "Pathoma_Husain_409",
        "title": "Pathoma_Husain",
        "content": "_____________11111, Table 15.1 Cushing Syndrome Low NIA NIA Tapering of steroids, if possible Transsphenoidal resection of pituitary ACTH-secreting adenoma; bilateral adrenalectomy in pituitary refractory cases can lead to enlargement adenoma (70%, of pituitary adenoma, resulting in may be present. Cushing disease) hyperpigmentation, headaches, and bitemporal hemianopsia (Nelson syndrome) Ectopic ACTH ACTH (e.g., small excess and No suppression Resection of ectopic source may be present. Adenomal Primary adrenal carcinoma with Resection of adenomalcarcinoma or adenoma (10%), contralateral Low NIA bilateral resection of hyperplasia with hyperplasia, or atrophy or F. Treatment generally involves surgical resection 1. Ketoconazole or metyrapone useful if surgery is not an option IV. CONGENITAL ADRENAL HYPERPLASIA A. Due to enzymatic defects in cortisol production; autosomal recessive 1. High ACTH (decreased negative feedback) leads to bilateral adrenal hyperplasia. 2.",
        "contents": "Pathoma_Husain. _____________11111, Table 15.1 Cushing Syndrome Low NIA NIA Tapering of steroids, if possible Transsphenoidal resection of pituitary ACTH-secreting adenoma; bilateral adrenalectomy in pituitary refractory cases can lead to enlargement adenoma (70%, of pituitary adenoma, resulting in may be present. Cushing disease) hyperpigmentation, headaches, and bitemporal hemianopsia (Nelson syndrome) Ectopic ACTH ACTH (e.g., small excess and No suppression Resection of ectopic source may be present. Adenomal Primary adrenal carcinoma with Resection of adenomalcarcinoma or adenoma (10%), contralateral Low NIA bilateral resection of hyperplasia with hyperplasia, or atrophy or F. Treatment generally involves surgical resection 1. Ketoconazole or metyrapone useful if surgery is not an option IV. CONGENITAL ADRENAL HYPERPLASIA A. Due to enzymatic defects in cortisol production; autosomal recessive 1. High ACTH (decreased negative feedback) leads to bilateral adrenal hyperplasia. 2."
    },
    {
        "id": "Pathology_Robbins_3426",
        "title": "Pathology_Robbins",
        "content": "Chronic pyelonephritis is a clinicopathologic entity in which interstitial inflammation and scarring of the renal parenchyma are associated with grossly visible scarring and deformity of the pelvicalyceal system in patients with a history of UTI. Chronic pyelonephritis is an important cause of chronic kidney disease. It can be divided into two forms: chronic obstructive pyelonephritis and chronic reflux\u2013associated pyelonephritis. As noted, obstruction predisposes the kidney to infection. Recurrent infections superimposed on diffuse or localized obstructive lesions lead to recurrent bouts of renal inflammation and scarring, which eventually cause chronic pyelonephritis. The disease can be bilateral, as with congenital anomalies of the urethra (e.g., posterior urethral valves), or unilateral, such as occurs with calculi and unilateral obstructive lesions of the ureter.",
        "contents": "Pathology_Robbins. Chronic pyelonephritis is a clinicopathologic entity in which interstitial inflammation and scarring of the renal parenchyma are associated with grossly visible scarring and deformity of the pelvicalyceal system in patients with a history of UTI. Chronic pyelonephritis is an important cause of chronic kidney disease. It can be divided into two forms: chronic obstructive pyelonephritis and chronic reflux\u2013associated pyelonephritis. As noted, obstruction predisposes the kidney to infection. Recurrent infections superimposed on diffuse or localized obstructive lesions lead to recurrent bouts of renal inflammation and scarring, which eventually cause chronic pyelonephritis. The disease can be bilateral, as with congenital anomalies of the urethra (e.g., posterior urethral valves), or unilateral, such as occurs with calculi and unilateral obstructive lesions of the ureter."
    },
    {
        "id": "Pathoma_Husain_373",
        "title": "Pathoma_Husain",
        "content": "III. CHRONIC PROSTATITIS A. Chronic inflammation of prostate B. Presents as dysuria with pelvic or low back pain C. Prostatic secretions show WBCs, but cultures are negative. IV. BENIGN PROSTATIC HYPERPLASIA (BPH) A. Hyperplasia of prostatic stroma and glands B. Age-related change (present in most men by the age of 60 years); no increased risk for cancer C. Related to dihydrotestosterone (DHT) 1. Testosterone is converted to DHT by Sa-reductase in stromal cells. 2. DHT acts on the androgen receptor of stromal and epithelial cells resulting in hyperplastic nodules. D. Occurs in the central periurethral zone of the prostate E. Clinical features include 1. 2. Impaired bladder emptying with increased risk for infection and hydronephrosis (Fig. 14.10) 3. Fig. 14.9 Normal prostate, microscopic Fig. 14.10 Hydronephrosis. appearance. 4. Hypertrophy of bladder wall smooth muscle; increased risk for bladder diverticula 5. Microscopic hematuria may be present. 6.",
        "contents": "Pathoma_Husain. III. CHRONIC PROSTATITIS A. Chronic inflammation of prostate B. Presents as dysuria with pelvic or low back pain C. Prostatic secretions show WBCs, but cultures are negative. IV. BENIGN PROSTATIC HYPERPLASIA (BPH) A. Hyperplasia of prostatic stroma and glands B. Age-related change (present in most men by the age of 60 years); no increased risk for cancer C. Related to dihydrotestosterone (DHT) 1. Testosterone is converted to DHT by Sa-reductase in stromal cells. 2. DHT acts on the androgen receptor of stromal and epithelial cells resulting in hyperplastic nodules. D. Occurs in the central periurethral zone of the prostate E. Clinical features include 1. 2. Impaired bladder emptying with increased risk for infection and hydronephrosis (Fig. 14.10) 3. Fig. 14.9 Normal prostate, microscopic Fig. 14.10 Hydronephrosis. appearance. 4. Hypertrophy of bladder wall smooth muscle; increased risk for bladder diverticula 5. Microscopic hematuria may be present. 6."
    },
    {
        "id": "article-19108_55",
        "title": "Histology, Cell -- Pathophysiology",
        "content": "Hyperplasia: It is a condition where the cells divide rapidly in number leading to an overall increase in the size of the structure. It can be physiological or pathological. The best example of a physiological type is the pregnant uterus. Pathologically it can be benign or malignant. Benign prostatic hyperplasia (BPH) is the best example of benign hyperplasia. The endometrial hyperplasia in the endometrial carcinoma is not infrequent. [24] Endometrial hyperplasia is a pathological state where the endometrial glandular tissue and stroma lining the uterus show severe hyperplastic changes.",
        "contents": "Histology, Cell -- Pathophysiology. Hyperplasia: It is a condition where the cells divide rapidly in number leading to an overall increase in the size of the structure. It can be physiological or pathological. The best example of a physiological type is the pregnant uterus. Pathologically it can be benign or malignant. Benign prostatic hyperplasia (BPH) is the best example of benign hyperplasia. The endometrial hyperplasia in the endometrial carcinoma is not infrequent. [24] Endometrial hyperplasia is a pathological state where the endometrial glandular tissue and stroma lining the uterus show severe hyperplastic changes."
    },
    {
        "id": "article-30833_28",
        "title": "Urethral Strictures -- History and Physical",
        "content": "Urethral strictures typically develop slowly and result in a progressive narrowing of the urethral lumen. Symptoms are similar to those typically\u00a0associated with bladder outlet obstruction due to benign prostatic hyperplasia, including a weak urinary stream, straining to void, incomplete emptying, double-voiding, intermittency, post-void dribbling, unexplained dysuria, and frequent UTIs. [8] [24] [25] Other presenting symptoms include acute urinary retention and hematuria.\u00a0Overall, 70% of patients with urethral strictures present with obstructive symptoms alone. [12]",
        "contents": "Urethral Strictures -- History and Physical. Urethral strictures typically develop slowly and result in a progressive narrowing of the urethral lumen. Symptoms are similar to those typically\u00a0associated with bladder outlet obstruction due to benign prostatic hyperplasia, including a weak urinary stream, straining to void, incomplete emptying, double-voiding, intermittency, post-void dribbling, unexplained dysuria, and frequent UTIs. [8] [24] [25] Other presenting symptoms include acute urinary retention and hematuria.\u00a0Overall, 70% of patients with urethral strictures present with obstructive symptoms alone. [12]"
    },
    {
        "id": "Pathoma_Husain_0",
        "title": "Pathoma_Husain",
        "content": "Growth Adaptations, Cellular Injury, and Cell Death I. BASIC PRINCIPLES A. An organ is in homeostasis with the physiologic stress placed on it. B. An increase, decrease, or change in stress on an organ can result in growth adaptations. II. HYPERPLASIA AND HYPERTROPHY A. An increase in stress leads to an increase in organ size. 1. Occurs via an increase in the size (hypertrophy) and/or the number (hyperplasia) of cells B. Hypertrophy involves gene activation, protein synthesis, and production of organelles. C. Hyperplasia involves the production of new cells from stem cells. D. Hyperplasia and hypertrophy generally occur together (e.g., uterus during pregnancy). 1. Permanent tissues (e.g., cardiac muscle, skeletal muscle, and nerve), however, cannot make new cells and undergo hypertrophy only. 2. For example, cardiac myocytes undergo hypertrophy, not hyperplasia, in response to systemic hypertension (Fig. 1.1).",
        "contents": "Pathoma_Husain. Growth Adaptations, Cellular Injury, and Cell Death I. BASIC PRINCIPLES A. An organ is in homeostasis with the physiologic stress placed on it. B. An increase, decrease, or change in stress on an organ can result in growth adaptations. II. HYPERPLASIA AND HYPERTROPHY A. An increase in stress leads to an increase in organ size. 1. Occurs via an increase in the size (hypertrophy) and/or the number (hyperplasia) of cells B. Hypertrophy involves gene activation, protein synthesis, and production of organelles. C. Hyperplasia involves the production of new cells from stem cells. D. Hyperplasia and hypertrophy generally occur together (e.g., uterus during pregnancy). 1. Permanent tissues (e.g., cardiac muscle, skeletal muscle, and nerve), however, cannot make new cells and undergo hypertrophy only. 2. For example, cardiac myocytes undergo hypertrophy, not hyperplasia, in response to systemic hypertension (Fig. 1.1)."
    },
    {
        "id": "article-26086_13",
        "title": "Obstructive Uropathy -- Treatment / Management",
        "content": "The treatment of obstructive uropathy is based around promptly addressing the obstructive process. Bladder volume measurements can help to guide further therapies from this point. A Foley catheter is likely to be attempted, particularly if the obstruction is due to the most frequent etiology, benign prostatic hypertrophy, or hyperplasia. [14] The initial attempt usually occurs with a 16- or 18-Fr Foley. The presence of obstruction may prevent the initial success of urethral catheterization and may require higher-level interventions. The most typical next step would be a trial of urethral catheterization using a Coud\u00e9 tip Foley, but more significant interventions may be required and are addressed in other articles. [15] [16] [17]",
        "contents": "Obstructive Uropathy -- Treatment / Management. The treatment of obstructive uropathy is based around promptly addressing the obstructive process. Bladder volume measurements can help to guide further therapies from this point. A Foley catheter is likely to be attempted, particularly if the obstruction is due to the most frequent etiology, benign prostatic hypertrophy, or hyperplasia. [14] The initial attempt usually occurs with a 16- or 18-Fr Foley. The presence of obstruction may prevent the initial success of urethral catheterization and may require higher-level interventions. The most typical next step would be a trial of urethral catheterization using a Coud\u00e9 tip Foley, but more significant interventions may be required and are addressed in other articles. [15] [16] [17]"
    },
    {
        "id": "Pathoma_Husain_253",
        "title": "Pathoma_Husain",
        "content": "V. A. Chronic inflammation of stomach mucosa B. Divided into two types based on underlying etiology: chronic autoimmune gastritis and chronic H pylori gastritis C. Chronic autoimmune gastritis is due to autoimmune destruction of gastric parietal cells, which are located in the stomach body and fundus. 1. Associated with antibodies against parietal cells and/or intrinsic factor; useful for diagnosis, but pathogenesis is mediated by T cells (type IV hypersensitivity) 2. i. Atrophy of mucosa with intestinal metaplasia (Fig. 10.11) ii. Achlorhydria with increased gastrin levels and antral G-cell hyperplasia iii. Megaloblastic (pernicious) anemia due to lack of intrinsic factor iv. Increased risk for gastric adenocarcinoma (intestinal type) D. Chronic H pylori gastritis is due to H pylori-induced acute and chronic inflammation; most common form of gastritis (90%) 1.",
        "contents": "Pathoma_Husain. V. A. Chronic inflammation of stomach mucosa B. Divided into two types based on underlying etiology: chronic autoimmune gastritis and chronic H pylori gastritis C. Chronic autoimmune gastritis is due to autoimmune destruction of gastric parietal cells, which are located in the stomach body and fundus. 1. Associated with antibodies against parietal cells and/or intrinsic factor; useful for diagnosis, but pathogenesis is mediated by T cells (type IV hypersensitivity) 2. i. Atrophy of mucosa with intestinal metaplasia (Fig. 10.11) ii. Achlorhydria with increased gastrin levels and antral G-cell hyperplasia iii. Megaloblastic (pernicious) anemia due to lack of intrinsic factor iv. Increased risk for gastric adenocarcinoma (intestinal type) D. Chronic H pylori gastritis is due to H pylori-induced acute and chronic inflammation; most common form of gastritis (90%) 1."
    }
]